Trial Profile
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Liver metastases; Oropharyngeal cancer; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transgene
- 11 Jul 2023 Results (n=43) published in the European Journal of Cancer
- 06 Jun 2023 Preliminary Results (n=59) assessing immunogenicity and clinical activity of TG4001 presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2023 Results presented in a Transgene media release.